Post-earnings recap
Reported
Fri, Nov 14, 2025
EPS actual
$-0.57
EPS est.
$-0.57
EPS surprise
-0.53%
1-day move
+8.61%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CG Oncology's earnings report indicates a challenging quarter with a larger-than-expected loss per share. Despite this, the stock rose by 8.61%, likely driven by investor optimism about future strategies discussed in the call. The lack of revenue data and guidance may leave some investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | -0.53% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about market conditions but remains focused on strategic initiatives. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.